抗动脉粥样硬化疫苗：最新进展
Vaccine against arteriosclerosis: an update.
作者信息
Chyu Kuang-Yuh, Dimayuga Paul C, Shah Prediman K
机构信息
Oppenheimer Atherosclerosis Research Center, Division of Cardiology, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cedars-Sinai Medical Center, 127 South San Vicente Blvd., Suite A-3307, Los Angeles, CA 90048, USA.
出版信息
Ther Adv Vaccines. 2017 Apr;5(2):39-47. doi: 10.1177/2051013617693753. Epub 2017 Feb 1.
Abstract
Substantial data from experimental and clinical investigation support the role of immune-mediated mechanisms in atherogenesis, with immune systems responding to many endogenous and exogenous antigens that play either proatherogenic or atheroprotective roles. An active immunization strategy against many of these antigens could potentially alter the natural history of atherosclerosis. This review mainly focuses on the important studies on the search for antigens that have been tested in vaccine formulations to reduce atherosclerosis in preclinical models. It will also address the opportunities and challenges associated with potential clinical application of this novel therapeutic paradigm.
摘要
来自实验和临床研究的大量数据支持免疫介导机制在动脉粥样硬化发生中的作用，免疫系统会对许多内源性和外源性抗原作出反应，这些抗原发挥着促动脉粥样硬化或抗动脉粥样硬化的作用。针对其中许多抗原的主动免疫策略可能会改变动脉粥样硬化的自然病程。本综述主要关注在临床前模型中测试过的用于减少动脉粥样硬化的疫苗制剂中寻找抗原的重要研究。它还将探讨这种新型治疗模式潜在临床应用所带来的机遇和挑战。
相似文献
1
Vaccine against arteriosclerosis: an update.抗动脉粥样硬化疫苗：最新进展
Ther Adv Vaccines. 2017 Apr;5(2):39-47. doi: 10.1177/2051013617693753. Epub 2017 Feb 1.
2
Vaccine for atherosclerosis.动脉粥样硬化疫苗。
J Am Coll Cardiol. 2014 Dec 30;64(25):2779-91. doi: 10.1016/j.jacc.2014.10.018.
3
Immunization for atherosclerosis.动脉粥样硬化的免疫治疗。
Curr Atheroscler Rep. 2007 Aug;9(2):104-9. doi: 10.1007/s11883-007-0005-8.
4
Immunotherapy for atherosclerosis: an emerging paradigm.动脉粥样硬化的免疫治疗：一种新兴模式。
Rev Cardiovasc Med. 2004 Fall;5(4):194-203.
5
Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis.病变发展及对免疫的反应揭示了CD4在动脉粥样硬化中具有复杂作用。
Circ Res. 2005 Mar 4;96(4):427-34. doi: 10.1161/01.RES.0000156889.22364.f1. Epub 2005 Jan 20.
6
Immunomodulation of atherosclerosis with a vaccine.用疫苗对动脉粥样硬化进行免疫调节。
Nat Clin Pract Cardiovasc Med. 2005 Dec;2(12):639-46. doi: 10.1038/ncpcardio0372.
7
Vaccination for atherosclerosis: a novel therapeutic paradigm.动脉粥样硬化的疫苗接种：一种新的治疗模式。
Expert Rev Vaccines. 2004 Dec;3(6):711-6. doi: 10.1586/14760584.3.6.711.
8
Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity.基因激活、载脂蛋白A-I/高密度脂蛋白、动脉粥样硬化预防与长寿
Pharmacol Toxicol. 1997 Aug;81(2):57-64. doi: 10.1111/j.1600-0773.1997.tb00032.x.
9
Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine.调节性 T 细胞在载脂蛋白 B 肽疫苗介导的抗动脉粥样硬化作用中的作用证据。
J Intern Med. 2011 May;269(5):546-56. doi: 10.1111/j.1365-2796.2010.02311.x. Epub 2010 Nov 29.
10
Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.Mif 缺乏有利于动脉粥样硬化中的抗动脉粥样硬化自身抗体表型。
FASEB J. 2018 Aug;32(8):4428-4443. doi: 10.1096/fj.201800058R. Epub 2018 Mar 15.
引用本文的文献
1
A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models.一种用于在小鼠模型中激活免疫并对动脉粥样硬化进行预防性保护的纳米疫苗。
Nat Commun. 2025 Mar 2;16(1):2111. doi: 10.1038/s41467-025-57467-5.
2
A bibliometric analysis of vaccination against atherosclerosis.一项关于抗动脉粥样硬化疫苗接种的文献计量分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2365500. doi: 10.1080/21645515.2024.2365500. Epub 2024 Jun 19.
3
Emerging Therapeutic Strategies in Cardiovascular Diseases.心血管疾病的新兴治疗策略
Cureus. 2024 Jul 12;16(7):e64388. doi: 10.7759/cureus.64388. eCollection 2024 Jul.
4
Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside.新兴疗法治疗动脉粥样硬化性心血管疾病：从基础到临床。
Int J Mol Sci. 2023 Apr 29;24(9):8062. doi: 10.3390/ijms24098062.
5
Effect of COVID-19 on Stress and Biomarkers: An Exploratory Cross-Sectional Study.2019冠状病毒病对压力和生物标志物的影响：一项探索性横断面研究。
Cureus. 2023 Mar 2;15(3):e35702. doi: 10.7759/cureus.35702. eCollection 2023 Mar.
6
A Disease Pathway Framework for Pain Point Identification and Elaboration of Product Requirements Across Patient Care Plan Using Innovation Think Tank Global Infrastructure.利用创新智库全球基础设施，为疼痛点识别和详细阐述跨患者护理计划的产品需求建立疾病途径框架。
Front Public Health. 2022 Apr 13;10:862384. doi: 10.3389/fpubh.2022.862384. eCollection 2022.
7
Reducing the Damage of Ox-LDL/LOX-1 Pathway to Vascular Endothelial Barrier Can Inhibit Atherosclerosis.降低 ox-LDL/LOX-1 通路对血管内皮屏障的损伤可抑制动脉粥样硬化。
Oxid Med Cell Longev. 2022 Mar 29;2022:7541411. doi: 10.1155/2022/7541411. eCollection 2022.
8
Vaccination against Atherosclerosis: Is It Real?动脉粥样硬化的疫苗接种：是否可行？
Int J Mol Sci. 2022 Feb 22;23(5):2417. doi: 10.3390/ijms23052417.
9
The journey of antimalarial drugs against SARS-CoV-2: Review article.抗疟药物对抗严重急性呼吸综合征冠状病毒2的历程：综述文章。
Inform Med Unlocked. 2021;24:100604. doi: 10.1016/j.imu.2021.100604. Epub 2021 May 19.
10
Retinoic Acid-Loaded Poly(lactic--glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis.载维甲酸聚（乳酸-乙醇酸）纳米粒制剂载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载载
J Biomed Nanotechnol. 2020 Apr 1;16(4):467-480. doi: 10.1166/jbn.2020.2905.
本文引用的文献
1
Monoclonal Antibodies for Lipid Management.用于血脂管理的单克隆抗体
Curr Atheroscler Rep. 2016 Jul;18(7):39. doi: 10.1007/s11883-016-0593-2.
2
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.针对残余心血管风险的未来血脂改变治疗选择。
Curr Cardiol Rep. 2016 Jul;18(7):65. doi: 10.1007/s11886-016-0743-8.
3
Adaptive Response of T and B Cells in Atherosclerosis.动脉粥样硬化中 T 和 B 细胞的适应性反应。
Circ Res. 2016 Feb 19;118(4):668-78. doi: 10.1161/CIRCRESAHA.115.306427.
4
Intranasal immunization with heat shock protein 60 induces CD4(+) CD25(+) GARP(+) and type 1 regulatory T cells and inhibits early atherosclerosis.用热休克蛋白60进行鼻内免疫可诱导CD4(+) CD25(+) GARP(+)和1型调节性T细胞，并抑制早期动脉粥样硬化。
Clin Exp Immunol. 2016 Mar;183(3):452-68. doi: 10.1111/cei.12726. Epub 2015 Nov 24.
5
A cholesterol-lowering VLP vaccine that targets PCSK9.一种靶向前蛋白转化酶枯草溶菌素9（PCSK9）的降胆固醇病毒样颗粒疫苗。
Vaccine. 2015 Oct 26;33(43):5747-5755. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26.
6
Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: Preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides.分枝杆菌热休克蛋白65（mbHSP65）诱导的动脉粥样硬化：预防性口服耐受及具有抗动脉粥样硬化和致动脉粥样硬化作用的mbHSP65肽的定义。
Atherosclerosis. 2015 Sep;242(1):303-10. doi: 10.1016/j.atherosclerosis.2015.06.044. Epub 2015 Jun 30.
7
Inflammation and immunity in diseases of the arterial tree: players and layers.动脉系统疾病中的炎症与免疫：参与者与层次
Circ Res. 2015 Jan 16;116(2):307-11. doi: 10.1161/CIRCRESAHA.116.301313.
8
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.基于肽的抗PCSK9疫苗——一种长期管理低密度脂蛋白胆固醇（LDLc）的方法。
PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014.
9
Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice.用晚期糖基化终产物修饰的低密度脂蛋白进行免疫可抑制糖尿病载脂蛋白E和低密度脂蛋白受体缺失小鼠的动脉粥样硬化进展。
Cardiovasc Diabetol. 2014 Nov 13;13:151. doi: 10.1186/s12933-014-0151-6.
10
The role of T and B cells in human atherosclerosis and atherothrombosis.T细胞和B细胞在人类动脉粥样硬化及动脉粥样硬化血栓形成中的作用。
Clin Exp Immunol. 2015 Feb;179(2):173-87. doi: 10.1111/cei.12477.
Zotero 插件